Literature DB >> 22710060

Insulin-producing cells from adult human bone marrow mesenchymal stem cells control streptozotocin-induced diabetes in nude mice.

Mahmoud M Gabr1, Mahmoud M Zakaria, Ayman F Refaie, Amani M Ismail, Mona A Abou-El-Mahasen, Sylvia A Ashamallah, Sherry M Khater, Sawsan M El-Halawani, Rana Y Ibrahim, Gan Shu Uin, Malgorzata Kloc, Roy Y Calne, Mohamed A Ghoneim.   

Abstract

Harvesting, expansion, and directed differentiation of human bone marrow-derived mesenchymal stem cells (BM-MSCs) could provide an autologous source of surrogate β-cells that would alleviate the limitations of availability and/or allogenic rejection following pancreatic or islet transplantation. Bone marrow cells were obtained from three adult type 2 diabetic volunteers and three nondiabetic donors. After 3 days in culture, adherent MSCs were expanded for two passages. At passage 3, differentiation was carried out in a three-staged procedure. Cells were cultured in a glucose-rich medium containing several activation and growth factors. Cells were evaluated in vitro by flow cytometry, immunolabeling, RT-PCR, and human insulin and c-peptide release in responses to increasing glucose concentrations. One thousand cell clusters were inserted under the renal capsule of diabetic nude mice followed by monitoring of their diabetic status. At the end of differentiation, ∼5-10% of cells were immunofluorescent for insulin, c-peptide or glucagon; insulin, and c-peptide were coexpressed. Nanogold immunolabeling for electron microscopy demonstrated the presence of c-peptide in the rough endoplasmic reticulum. Insulin-producing cells (IPCs) expressed transcription factors and genes of pancreatic hormones similar to those expressed by pancreatic islets. There was a stepwise increase in human insulin and c-peptide release by IPCs in response to increasing glucose concentrations. Transplantation of IPCs into nude diabetic mice resulted in control of their diabetic status for 3 months. The sera of IPC-transplanted mice contained human insulin and c-peptide but negligible levels of mouse insulin. When the IPC-bearing kidneys were removed, rapid return of diabetic state was noted. BM-MSCs from diabetic and nondiabetic human subjects could be differentiated without genetic manipulation to form IPCs that, when transplanted, could maintain euglycemia in diabetic mice for 3 months. Optimization of the culture conditions are required to improve the yield of IPCs and their functional performance.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710060      PMCID: PMC3893040          DOI: 10.3727/096368912X647162

Source DB:  PubMed          Journal:  Cell Transplant        ISSN: 0963-6897            Impact factor:   4.064


  43 in total

1.  Purification and ex vivo expansion of postnatal human marrow mesodermal progenitor cells.

Authors:  M Reyes; T Lund; T Lenvik; D Aguiar; L Koodie; C M Verfaillie
Journal:  Blood       Date:  2001-11-01       Impact factor: 22.113

2.  Pluripotency of mesenchymal stem cells derived from adult marrow.

Authors:  Yuehua Jiang; Balkrishna N Jahagirdar; R Lee Reinhardt; Robert E Schwartz; C Dirk Keene; Xilma R Ortiz-Gonzalez; Morayma Reyes; Todd Lenvik; Troy Lund; Mark Blackstad; Jingbo Du; Sara Aldrich; Aaron Lisberg; Walter C Low; David A Largaespada; Catherine M Verfaillie
Journal:  Nature       Date:  2002-06-20       Impact factor: 49.962

3.  Differentiation of embryonic stem cells to insulin-secreting structures similar to pancreatic islets.

Authors:  N Lumelsky; O Blondel; P Laeng; I Velasco; R Ravin; R McKay
Journal:  Science       Date:  2001-04-26       Impact factor: 47.728

Review 4.  Electron microscopy, immunostaining, cytoskeleton visualization, in situ hybridization, and three-dimensional reconstruction of Xenopus oocytes.

Authors:  Szczepan M Bilinski; Mariusz K Jaglarz; Matthew T Dougherty; Malgorzata Kloc
Journal:  Methods       Date:  2009-12-16       Impact factor: 3.608

Review 5.  Minireview: the glucagon-like peptides.

Authors:  D J Drucker
Journal:  Endocrinology       Date:  2001-02       Impact factor: 4.736

6.  neurogenin3 is required for the development of the four endocrine cell lineages of the pancreas.

Authors:  G Gradwohl; A Dierich; M LeMeur; F Guillemot
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

7.  In-vitro differentiation of pancreatic beta-cells.

Authors:  B Soria
Journal:  Differentiation       Date:  2001-10       Impact factor: 3.880

8.  Independent development of pancreatic alpha- and beta-cells from neurogenin3-expressing precursors: a role for the notch pathway in repression of premature differentiation.

Authors:  J Jensen; R S Heller; T Funder-Nielsen; E E Pedersen; C Lindsell; G Weinmaster; O D Madsen; P Serup
Journal:  Diabetes       Date:  2000-02       Impact factor: 9.461

Review 9.  Bone marrow and pancreatic islets: an old story with new perspectives.

Authors:  Fabio Ciceri; Lorenzo Piemonti
Journal:  Cell Transplant       Date:  2010-08-17       Impact factor: 4.064

10.  Transplantation of insulin-producing cells derived from umbilical cord stromal mesenchymal stem cells to treat NOD mice.

Authors:  Hwai-Shi Wang; Jia-Fwu Shyu; Wen-Sheng Shen; Hsin-Chi Hsu; Torng-Chien Chi; Chie-Pein Chen; Seng-Wong Huang; Yi-Ming Shyr; Kam-Tsun Tang; Tien-Hua Chen
Journal:  Cell Transplant       Date:  2010-08-18       Impact factor: 4.064

View more
  35 in total

1.  Type 1 Diabetes Mellitus Donor Mesenchymal Stromal Cells Exhibit Comparable Potency to Healthy Controls In Vitro.

Authors:  Lindsay C Davies; Jessica J Alm; Nina Heldring; Guido Moll; Caroline Gavin; Ioannis Batsis; Hong Qian; Mikael Sigvardsson; Bo Nilsson; Lauri E Kyllonen; Kaija T Salmela; Per-Ola Carlsson; Olle Korsgren; Katarina Le Blanc
Journal:  Stem Cells Transl Med       Date:  2016-07-13       Impact factor: 6.940

2.  Human urine-derived stem cells play a novel role in the treatment of STZ-induced diabetic mice.

Authors:  Tianxue Zhao; Deng Luo; Yun Sun; Xin Niu; Yang Wang; Chen Wang; Weiping Jia
Journal:  J Mol Histol       Date:  2018-04-19       Impact factor: 2.611

3.  Differentiation Potential of Nestin (+) and Nestin (-) Cells Derived from Human Bone Marrow Mesenchymal Stem Cells into Functional Insulin Producing Cells.

Authors:  Sahar Rashed; Mahmoud Gabr; Abdel-Aziz Abdel-Aziz; Mahmoud Zakaria; Sherry Khater; Amani Ismail; Ali Fouad; Ayman Refaie
Journal:  Int J Mol Cell Med       Date:  2019-07-17

Review 4.  Impact of Diabetes Mellitus on Human Mesenchymal Stromal Cell Biology and Functionality: Implications for Autologous Transplantation.

Authors:  Marwa Mahmoud; Nourhan Abu-Shahba; Osama Azmy; Nagwa El-Badri
Journal:  Stem Cell Rev Rep       Date:  2019-04       Impact factor: 5.739

5.  In vitro differentiation of human umbilical cord Wharton's jelly mesenchymal stromal cells to insulin producing clusters.

Authors:  Seideh Masoomeh Nekoei; Negar Azarpira; Ladan Sadeghi; Sulmaz Kamalifar
Journal:  World J Clin Cases       Date:  2015-07-16       Impact factor: 1.337

Review 6.  Stem cell therapy to cure type 1 diabetes: from hype to hope.

Authors:  Preeti Chhabra; Kenneth L Brayman
Journal:  Stem Cells Transl Med       Date:  2013-04-09       Impact factor: 6.940

7.  Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells into Insulin-Producing Cells: Evidence for Further Maturation In Vivo.

Authors:  Mahmoud M Gabr; Mahmoud M Zakaria; Ayman F Refaie; Sherry M Khater; Sylvia A Ashamallah; Amani M Ismail; Sawsan M El-Halawani; Mohamed A Ghoneim
Journal:  Biomed Res Int       Date:  2015-05-12       Impact factor: 3.411

Review 8.  From Mesenchymal Stromal/Stem Cells to Insulin-Producing Cells: Immunological Considerations.

Authors:  Ayman F Refaie; Batoul L Elbassiouny; Malgorzata Kloc; Omaima M Sabek; Sherry M Khater; Amani M Ismail; Rania H Mohamed; Mohamed A Ghoneim
Journal:  Front Immunol       Date:  2021-06-23       Impact factor: 7.561

9.  Bone marrow stem cell as a potential treatment for diabetes.

Authors:  Ming Li; Susumu Ikehara
Journal:  J Diabetes Res       Date:  2013-04-10       Impact factor: 4.011

10.  Mesenchymal stem cell therapy in diabetes mellitus: progress and challenges.

Authors:  Nagwa El-Badri; Mohamed A Ghoneim
Journal:  J Nucleic Acids       Date:  2013-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.